DeepMed Research

Aliskiren

Generic Name: Aliskiren

Brand Names: Rasilez, Tekturna, Tekturna Hct

Drug Type: Small Molecule

Chemical Formula: C_₃₀H_₅₃N_₃O_₆

CAS Number: 173334-57-1

Unique Ingredient Identifier: 502FWN4Q32

Background: Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.

Indication: Aliskiren is used for the treatment of hypertension in children above 6 years and adults. This drug may also be used in conjunction with antihypertensives such as calcium channel blockers and thiazides in products form to provide additional blood pressure control.

Associated Conditions: Hypertension

Clinical Trials

Non-Inferiority Study of Aliskiren vs Losartan in the Treatment of Hypertension With Hyperuricemia

Phase 4

Completed

Conditions: Hypertension,Essential
Hyperuricemia

Interventions: Drug: Aliskiren
Drug: Losartan

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-05

Lead Sponsor: Hansung University

Target Recruit Count: 66

Registration Number: NCT06718062

Locations: 🇨🇳
Chancheng District People's Hospital, Foshan City, Foshan, Guangdong, China

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

Phase 2

Recruiting

Conditions: Membranoproliferative Glomerulonephritis
Dense Deposit Disease
C3 Glomerulopathy
Complement Abnormality
C3 Glomerulonephritis

Interventions: Drug: Aliskiren
Drug: Enalapril

First Posted Date: 2019-12-03

Last Posted Date: 2024-06-18

Lead Sponsor: Region Skane

Target Recruit Count: 30

Registration Number: NCT04183101

Locations: 🇸🇪
Akademiska sjukhuset, Uppsala, Sweden
🇸🇪
Region Skåne Skåne Universitetssjukhus, Lund, Sweden
🇸🇪
Sahlgrenska Hospital, Gothenburg, Sweden

and more 1 locations

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

Phase 4

Completed

Conditions: High Blood Pressure

Interventions: Drug: Aliskiren 150 mg
Drug: Placebo
Drug: HCTZ
Drug: Aliskiren 300 mg

First Posted Date: 2017-04-14

Last Posted Date: 2017-08-25

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 31

Registration Number: NCT03115853

Locations: 🇺🇸
VUMC, Nashville, Tennessee, United States

Role of ALiskiren, a Direct Renin Inhibitor, in Preventing Atrial Fibrillation in Patients With a Pacemaker; RALF.

Phase 3

Conditions: Atrial Fibrillation

Interventions: Drug: aliskiren

First Posted Date: 2016-09-21

Last Posted Date: 2016-09-21

Lead Sponsor: Mika Lehto

Target Recruit Count: 70

Registration Number: NCT02909166

Locations: 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland

Influence of Aliskiren on Albuminuria After Kidney Transplantation

Not Applicable

Completed

Conditions: Albuminuria

Interventions: Drug: aliskiren
Drug: losartan
Other: Placebo

First Posted Date: 2015-05-18

Last Posted Date: 2015-05-18

Lead Sponsor: Medical University of Gdansk

Target Recruit Count: 18

Registration Number: NCT02446548

Locations: 🇵🇱
Medical University of Gdansk, Gdansk, Pomorskie, Poland

Aliskiren Study of Safety and Efficacy in Senior Hypertensives

Phase 4

Withdrawn

Conditions: Hypertension

Interventions: Drug: Aliskiren
Drug: Amlodipine
Drug: Ramipril
Drug: Hydrochlorothiazide

First Posted Date: 2013-08-14

Last Posted Date: 2015-04-16

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT01922141

Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy

Phase 4

Conditions: Hypertensive Left Ventricular Hypertrophy

Interventions: Drug: Aliskiren
Drug: Eplerenone

First Posted Date: 2013-07-09

Last Posted Date: 2013-07-22

Lead Sponsor: Nagoya University

Target Recruit Count: 100

Registration Number: NCT01893788

Locations: 🇯🇵
Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan

RAS Quantification in Patients With Aliskiren or Candesartan

Phase 4

Completed

Conditions: Hypertension
Chronic Kidney Disease
Proteinuria

Interventions: Other: RAS blockade discontinuation
Drug: Aliskiren
Drug: Candesartan

First Posted Date: 2013-04-09

Last Posted Date: 2016-03-16

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 24

Registration Number: NCT01827202

Locations: 🇦🇹
Medical University of Vienna, Department of Internal Medicine III, Division of Nephrology and Dialysis, Vienna, Austria

Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS

Phase 3

Completed

Conditions: Marfan Syndrome

Interventions: Drug: Aliskiren
Drug: Atenolol

First Posted Date: 2012-10-26

Last Posted Date: 2017-06-05

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 30

Registration Number: NCT01715207

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

RAAS Inhibitor Drugs in Dialysis Patients

Phase 4

Conditions: Hypertension
End Stage Renal Disease

Interventions: Drug: aliskiren

First Posted Date: 2012-07-09

Last Posted Date: 2012-07-09

Lead Sponsor: University of Campania "Luigi Vanvitelli"

Target Recruit Count: 350

Registration Number: NCT01635387

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy